June 26 (Reuters) - Medical device maker Medtronic's (MDT.N), opens new tab finance chief Karen Parkhill will depart the medical device maker to join HP Inc (HPQ.N), opens new tab as CFO, the companies said on Wednesday, amid the PC industry's recovery from its extended post-pandemic slump.
The FDA is alerting healthcare providers to a software recall from Medtronic for its neurosurgery navigation software after reports of potentially inaccurate measurements being displayed during brain procedures.
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital...
Medtronic has received approval from the National Medical Products Administration (NMPA) in China for its Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure. Symplicity Spyral is the first RDN system in China to receive NMPA approval. The company intends to go through the provincial registration process and expects sales of Symplicity Spyral in China to be modest in the short-term.
DUBLIN and ATLANTA, April 7, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Session and simultaneously published in The New England Journal of Medicine. The one-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial in individuals with aortic stenosis (AS) with small aortic annuli (SAA) demonstrated noninferior clinical outcomes and superior valve performance as measured by bioprosthetic valve dysfunction performance for the Evolut™ TAVR platform compared to the SAPIEN™ platform.
Medtronic opens its expanded innovation centre in Hyderabad
Medtronic lifts annual profit forecast, exits ventilator business
Dec 13 (Reuters) - Medtronic (MDT.N) said on Wednesday that the U.S. Food and Drug Administration (FDA) had approved its system for a type of condition that can cause stroke or heart failure.
DUBLIN, Dec. 7, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 7, 2023, approved the company's cash dividend for the third quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2023. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 consecutive years. The dividend is payable on January 12, 2024, to shareholders of record at the close of business on December 20, 2023.
Nov 21 (Reuters) - Medtronic (MDT.N) raised its annual earnings forecast on Tuesday as strong sales in its surgical and diabetes units allayed concerns about the impact of new diabetes and weight-loss drugs on long-term growth, sending its shares up nearly 4% in morning trade.